{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:03:26Z","timestamp":1788314606951,"version":"build-2803163510"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Numerous practical issues must be considered when combining targeted therapies in early clinical drug development. These include tumor resistance mechanisms, the existence of multiple, redundant signaling pathways, and the failure of single-agent therapies to achieve cures. The strategies adopted to examine combinatorial therapy include the goal of hitting more than one target by specifically inhibiting signal transduction cascades and suppressing specific mechanisms of action with the use of multitargeted kinase inhibitors made possible by high-throughput screening techniques, combinatorial chemistry, and chemoinformatics. Two complex considerations are: which agents to combine given the heterogeneity of tumors and their various underlying perturbations, including secondary mutations and feedback loops, and how to translate findings from the bench to the bedside or directly from the bedside. Another consideration is: When is there enough information to provide a rationale for instituting a phase I trial? Various strategies have been used in combining molecules, including targeting diverse pathways, inhibiting upstream and downstream signals, and adopting a synthetic lethality paradigm. Other issues are: determining appropriate target populations for treatment, how to combine therapeutics with diagnostics, and the frequency of targets in patients referred to clinical trials. Here, we review these issues and we propose various novel trial designs that are logical for determining the efficacy of a drug or drug combination for personalized treatment. A difficult issue that must be answered is how many and which drugs to combine. Recent technologies, such as multiplexed assay platforms and bioinformatics, will shape the future of clinical trials and help answer these questions surrounding combinatorial treatment.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0117","type":"journal-article","created":{"date-parts":[[2010,1,16]],"date-time":"2010-01-16T01:35:23Z","timestamp":1263605723000},"page":"37-50","source":"Crossref","is-referenced-by-count":47,"title":["Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside"],"prefix":"10.1093","volume":"15","author":[{"given":"Jordi","family":"Rodon","sequence":"first","affiliation":[{"name":"a Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA"},{"name":"b Medical Oncology Program, Vall d Hebron Institut de Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Perez","sequence":"additional","affiliation":[{"name":"b Medical Oncology Program, Vall d Hebron Institut de Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"a Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,1,15]]},"reference":[{"key":"2021122207232652900_R1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122207232652900_R2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122207232652900_R3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.pharmtox.45.120403.100124","article-title":"Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics","volume":"45","author":"Tibes","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2021122207232652900_R5","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R6","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R7","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer\u2014molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122207232652900_R9","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","article-title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R10","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","article-title":"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235","volume":"68","author":"Eichhorn","year":"2008","journal-title":"Cancer Res"},{"key":"2021122207232652900_R11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"2021122207232652900_R12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials","volume":"355","author":"Prostate Cancer Trialists' Collaborative Group","year":"2000","journal-title":"Lancet"},{"key":"2021122207232652900_R13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207232652900_R14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study","volume":"92","author":"Klijn","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122207232652900_R15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122207232652900_R16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207232652900_R17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: A suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2021122207232652900_R18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/annonc\/mdg316","article-title":"The Hsp90 chaperone complex as a novel target for cancer therapy","volume":"14","author":"Goetz","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122207232652900_R19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2174\/1381612053507567","article-title":"A mechanistic approach to anticancer therapy: Targeting the cell cycle with histone deacetylase inhibitors","volume":"11","author":"Mork","year":"2005","journal-title":"Curr Pharm Des"},{"key":"2021122207232652900_R20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nchembio.117","article-title":"Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases","volume":"4","author":"Apsel","year":"2008","journal-title":"Nat Chem Biol"},{"key":"2021122207232652900_R21","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1158\/1078-0432.CCR-05-2436","article-title":"Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer","volume":"12","author":"Kiewe","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122207232652900_R22","doi-asserted-by":"crossref","first-page":"19665","DOI":"10.1074\/jbc.M500815200","article-title":"A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity","volume":"280","author":"Lu","year":"2005","journal-title":"J Biol Chem"},{"key":"2021122207232652900_R23","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","article-title":"Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor","volume":"66","author":"Bauer","year":"2006","journal-title":"Cancer Res"},{"key":"2021122207232652900_R24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djh182","article-title":"Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice","volume":"96","author":"Parulekar","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122207232652900_R25","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/JCO.2007.12.0949","article-title":"Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R26","volume-title":"Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab and bevacizumab as first line treatment of HER2-amplified breast cancer","author":"Pegram","year":"2006"},{"key":"2021122207232652900_R27","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207232652900_R28","doi-asserted-by":"crossref","first-page":"38953","DOI":"10.1074\/jbc.C000684200","article-title":"MEK inhibition enhances paclitaxel-induced tumor apoptosis","volume":"275","author":"MacKeigan","year":"2000","journal-title":"J Biol Chem"},{"key":"2021122207232652900_R29","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"2021122207232652900_R30","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"2021122207232652900_R31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat Med"},{"key":"2021122207232652900_R32","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207232652900_R33","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"2021122207232652900_R34","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/emboj.2008.61","article-title":"A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor","volume":"27","author":"Turner","year":"2008","journal-title":"EMBO J"},{"key":"2021122207232652900_R35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nchembio1207-739","article-title":"Recognizing and exploiting differences between RNAi and small-molecule inhibitors","volume":"3","author":"Weiss","year":"2007","journal-title":"Nat Chem Biol"},{"key":"2021122207232652900_R36","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R37","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"2021122207232652900_R38","article-title":"Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: Results of a post-hoc analysis from the TAnDEM study","volume":"46","author":"Clemens","year":"2007","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"2021122207232652900_R39","volume-title":"First-Line Therapy With Lapatinib Combined with Letrozole vs Letrozole Alone for Postmenopausal Hormone Receptor Positive MBC: First Results from the Phase III Double-Bind EGF 30008 Trial","author":"Johnston","year":"2008"},{"key":"2021122207232652900_R40","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-04-0562","article-title":"Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor","volume":"64","author":"Huang","year":"2004","journal-title":"Cancer Res"},{"key":"2021122207232652900_R41","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/onc.2008.432","article-title":"Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity","volume":"28","author":"Scaltriti","year":"2009","journal-title":"Oncogene"},{"key":"2021122207232652900_R42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccr.2008.03.015","article-title":"Survival of cancer cells is maintained by EGFR independent of its kinase activity","volume":"13","author":"Weihua","year":"2008","journal-title":"Cancer Cell"},{"key":"2021122207232652900_R43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bjc.6604269","article-title":"Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs","volume":"98","author":"Bianco","year":"2008","journal-title":"Br J Cancer"},{"key":"2021122207232652900_R44","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Buck","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2021122207232652900_R45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/JTO.0b013e3181653d1b","article-title":"Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): A phase I study","volume":"3","author":"Ramalingam","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2021122207232652900_R46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"2021122207232652900_R47","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1073\/pnas.0510284103","article-title":"Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors","volume":"103","author":"Ji","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207232652900_R48","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122207232652900_R49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122207232652900_R50","volume-title":"Directed Discovery of Novel Drug Cocktails. Santa Fe Institute Working Paper No. 05\u201307-031","author":"Miller","year":"2005"},{"key":"2021122207232652900_R51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/msb.2008.53","article-title":"Models from experiments: Combinatorial drug perturbations of cancer cells","volume":"4","author":"Nelander","year":"2008","journal-title":"Mol Syst Biol"},{"key":"2021122207232652900_R52","volume-title":"Microangiopathic Hemolytic Anemia (MAHA) in Patients Treated with Avastin\u00ae (Bevacizumab) and Sunitinib Malate","author":"U.S. Food and Drug Administration."},{"key":"2021122207232652900_R53","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1038\/sj.onc.1209685","article-title":"HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy","volume":"25","author":"Wen","year":"2006","journal-title":"Oncogene"},{"key":"2021122207232652900_R54","first-page":"2609","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins","volume":"118","author":"Guix","year":"2008","journal-title":"J Clin Invest"},{"issue":"18 suppl","key":"2021122207232652900_R55","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/jco.2007.25.18_suppl.3512","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies","volume":"25","author":"Patnaik","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R56","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1208\/s12248-009-9106-3","article-title":"Predicting drug-drug interactions: An FDA perspective","volume":"11","author":"Zhang","year":"2009","journal-title":"AAPS J"},{"key":"2021122207232652900_R57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tiv.2005.06.049","article-title":"In vitro methods in human drug biotransformation research: Implications for cancer chemotherapy","volume":"20","author":"Hariparsad","year":"2006","journal-title":"Toxicol In Vitro"},{"key":"2021122207232652900_R58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.drudis.2007.07.022","article-title":"Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects","volume":"12","author":"Aszalos","year":"2007","journal-title":"Drug Discov Today"},{"key":"2021122207232652900_R59","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/1389200043335414","article-title":"Human hepatocytes in primary culture: The choice to investigate drug metabolism in man","volume":"5","author":"G\u00f3mez-Lech\u00f3n","year":"2004","journal-title":"Curr Drug Metab"},{"key":"2021122207232652900_R60","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/0091270007306958","article-title":"Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: Reality check","volume":"47","author":"Seitz","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2021122207232652900_R61","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/jnci\/95.23.1744","article-title":"For investigational targeted drugs, combination trials pose challenges","volume":"95","author":"Goldman","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122207232652900_R62","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.2007.13.5913","article-title":"Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III","volume":"26","author":"El-Maraghi","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R63","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-07-4562","article-title":"Oncologic phase 0 trials incorporating clinical pharmacodynamics: From concept to patient","volume":"14","author":"Doroshow","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122207232652900_R64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc2066","article-title":"Compressing drug development timelines in oncology using phase '0\u2032 trials","volume":"7","author":"Kummar","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2021122207232652900_R65","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1200\/JCO.2007.12.1012","article-title":"Translation of innovative designs into phase I trials","volume":"25","author":"Rogatko","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R66","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/ijc.21461","article-title":"Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation","volume":"118","author":"Bertelsen","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122207232652900_R67","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent mutation of the PIK3CA gene in ovarian and breast cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122207232652900_R68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"2021122207232652900_R69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.clpt.6100063","article-title":"The prospects for \u201cpersonalized medicine\u201d in drug development and drug therapy","volume":"81","author":"Woodcock","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2021122207232652900_R70","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","article-title":"Clinical biomarkers in drug discovery and development","volume":"2","author":"Frank","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2021122207232652900_R71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.drudis.2007.02.004","article-title":"Driving earlier clinical attrition: If you want to find the needle, burn down the haystack. Considerations for biomarker development","volume":"12","author":"Peck","year":"2007","journal-title":"Drug Discov Today"},{"key":"2021122207232652900_R72","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1371\/journal.pone.0000484","article-title":"Whole-genome sequencing and assembly with high-throughput, short-read technologies","volume":"2","author":"Sundquist","year":"2007","journal-title":"PLoS One"},{"key":"2021122207232652900_R73","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.seminoncol.2006.04.014","article-title":"Pursuing therapeutic targets that are and are not there: A tumor's context of vulnerability","volume":"33","author":"Von Hoff","year":"2006","journal-title":"Semin Oncol"},{"issue":"1 suppl","key":"2021122207232652900_R74","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/CCM.0b013e3181921349","article-title":"Toward theragnostics","volume":"37","author":"Pene","year":"2009","journal-title":"Crit Care Med"},{"issue":"18 suppl","key":"2021122207232652900_R75","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1200\/jco.2006.24.18_suppl.3071","article-title":"Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents","volume":"24","author":"Von Hoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R76","volume-title":"ClinicalTrials.gov. Molecular Profiling Protocol (SCRI-CA-001)","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R77","volume-title":"ClinicalTrials.gov. BATTLE Program: Umbrella Protocol for Patients With NSCLC","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R78","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.2008.18.9621","article-title":"Cancer: The road to Amiens","volume":"27","author":"Stewart","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207232652900_R79","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1125951","article-title":"Targeting tyrosine kinases in cancer: The second wave","volume":"312","author":"Baselga","year":"2006","journal-title":"Science"},{"key":"2021122207232652900_R80","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"2021122207232652900_R81","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"2021122207232652900_R82","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature03799","article-title":"Genes that mediate breast cancer metastasis to lung","volume":"436","author":"Minn","year":"2005","journal-title":"Nature"},{"key":"2021122207232652900_R83","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"2021122207232652900_R84","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2217\/14622416.7.7.1087","article-title":"Metabolomics-based systems biology and personalized medicine: Moving towards n = 1 clinical trials?","volume":"7","author":"Greef","year":"2006","journal-title":"Pharmacogenomics"},{"key":"2021122207232652900_R85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ncpuro0669","article-title":"Technology insight: Will systems pathology replace the pathologist?","volume":"4","author":"Saidi","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"2021122207232652900_R86","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ncponc0744","article-title":"Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions","volume":"4","author":"Bentzen","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"2021122207232652900_R87","volume-title":"ClinicalTrials.gov. AZD2281 and Carboplatin in Treating Patients With BRCA1\/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial Cancer","author":"U.S. National Institutes of Health."},{"issue":"suppl 19","key":"2021122207232652900_R88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/sonc.2002.37349","article-title":"Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma","volume":"29","author":"Bourhis","year":"2002","journal-title":"Semin Oncol"},{"key":"2021122207232652900_R89","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0360-3016(00)01488-7","article-title":"Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation","volume":"49","author":"Harari","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122207232652900_R90","volume-title":"ClinicalTrials.gov. Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R91","volume-title":"ClinicalTrials.gov. Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2\/Neu Overexpression","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R92","first-page":"23","volume-title":"Cancer Management: A Multidisciplinary Approach","author":"Takimoto","year":"2005","edition":"Ninth Edition."},{"key":"2021122207232652900_R93","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00280-008-0811-x","article-title":"Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors","volume":"63","author":"Lin","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122207232652900_R94","volume-title":"ClinicalTrials.gov. Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R95","volume-title":"ClinicalTrials.gov. Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R96","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/1078-0432.CCR-06-0112","article-title":"A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer","volume":"12","author":"Reckamp","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122207232652900_R97","volume-title":"Study Summary: No. 2005\u20130794","author":"The University of Texas MD Anderson Cancer Center."},{"key":"2021122207232652900_R98","volume-title":"ClinicalTrials.gov. A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R99","doi-asserted-by":"crossref","first-page":"s4628","DOI":"10.1158\/1078-0432.CCR-07-0717","article-title":"Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer","volume":"13","author":"Johnson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122207232652900_R100","volume-title":"ClinicalTrials.gov. Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer","author":"U.S. National Institutes of Health."},{"key":"2021122207232652900_R101","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/annonc\/mdn689","article-title":"Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205","volume":"20","author":"Li","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122207232652900_R102","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0117","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/1\/37\/41842838\/oncolo_15_1_37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/1\/37\/41842838\/oncolo_15_1_37.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:17:10Z","timestamp":1640161030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/1\/37\/6399087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,1]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1,15]]},"published-print":{"date-parts":[[2010,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0117","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,1,1]]},"published":{"date-parts":[[2010,1,1]]}}}